Recent Updates
Recently added Catalysts
BioImpact Capital 13F Holdings (Q2 2026)
According to its SEC 13F filed on Aug 14, 2026, BioImpact Capital reported 37 long positions worth $1.64B as of Jun 30, 2026. CGEM is 10.8% of the portfolio and the top 10 holdings are 55%. Against Q1 2026 it opened 7 new positions, added to 7, trimmed 22 and exited 11. 6 holdings have a dated FDA decision or data readout in the next 90 days, and 13 more expect one in a stated window such as "H2 2026".
Holdings
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
 FBRX | Forte Biosciences, Inc. | 987.45 K | 20.98 M | 1.3 | Trimmed -1% | Clinical | Expected 2026 Phase 2 topline data readout | ||
 CORT | Corcept Therapeutics, Inc. | 771.03 K | 67.04 M | 4.1 | Trimmed -22% | Commercial | Expected Year-end 2026 Phase 2b data readout | ||
 QURE | Uniqure NV | 1.23 M | 56.46 M | 3.4 | Trimmed -10% | Clinical | None in 90 days | ||
 ORIC | Oric Pharmaceuticals Inc | 1.88 M | 20.38 M | 1.2 | Added +4% | Clinical | None in 90 days | ||
 URGN | Urogen Pharma Ltd | 933.41 K | 34.35 M | 2.1 | Trimmed -1% | Commercial | Expected 2H 2026 NDA Submission | ||
 NTRA | Natera Inc | 92.64 K | 25.15 M | 1.5 | Trimmed 0% | — | None in 90 days |
Top 20 Holdings
Size = share of the portfolio. Option positions show CALL or PUT.
Who else owns these stocks?
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
Questions about BioImpact Capital's 13F
What does BioImpact Capital own?
37 stocks worth $1.64B at Jun 30, 2026, as reported in its 13F, led by CGEM (10.8% of the portfolio). The full list is in the Holdings table above.
What did it buy and sell last quarter?
Against Q1 2026: 7 new positions, 7 increases, 22 reductions and 11 full exits, from its 13F filings.
How current is this data?
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.
Why are some positions labelled CALL or PUT?
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by BIOIMPACT CAPITAL LLC, accession 0001193125-26-352199, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.